The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza,1 has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
DRUGS FOR WEIGHT LOSS – Pharmacologic treatment of obesity has been limited by modest efficacy, adverse effects, low adherence rates, and regain of weight with drug cessation.2 Drugs approved by the FDA for long-term treatment of obesity are listed in Table 2.
Phentermine/topiramate ER (Qsymia) is the most effective drug available to date for weight loss. Lorcaserin (Belviq) is only modestly effective, but is generally well tolerated.3 The lipase
- Drugs for Psoriasis
- Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
- Recombinant Human Parathyroid Hormone (Natpara)
- Drugs for Psoriatic Arthritis (online only)
An article published in the New York Times on May 1, 2015 listed the 10 drugs on which Medicare Part D spent the most in 2013. The most costly ($2.53 billion) was the proton pump inhibitor (PPI) Nexium (esomeprazole magnesium), which has recently become available generically.
EFFICACY AND TOLERABILITY – PPIs are effective in relieving symptoms of gastroesophageal reflux disease (GERD) and in healing erosive esophagitis and peptic ulcers, and they are generally well tolerated. There is no convincing evidence that any one PPI is more effective or better tolerated than any other.1,2
DRUG INTERACTIONS – Omeprazole and esomeprazole are inhibitors of CYP2C19 and can increase serum concentrations of drugs metabolized by this pathway, such as diazepam (Valium, and generics) and phenytoin (Dilantin, and others). They can also inhibit conversion of the antiplatelet drug clopidogrel (Plavix, and